Amino acid sequence diversity within the family of antibodies bearing the major antiarsonate cross-reactive idiotype of the A strain mouse by unknown
AMINO  ACID  SEQUENCE  DIVERSITY  WITHIN  THE 
FAMILY  OF  ANTIBODIES  BEARING  THE  MAJOR 
ANTIARSONATE  CROSS-REACTIVE  IDIOTYPE 
OF  THE  A  STRAIN  MOUSE* 
BY  CLIVE A.  SLAUGHTER AND J.  DONALD CAPRA 
From the Department of Microbiology,  The University of Texas Health Science Center at Dallas, 
Dallas, Texas 75235 
An uneasy consensus of opinion is being reached concerning the genetic basis 
of antibody diversity (1).  This consensus, which includes elements of both the 
original "germline" and "somatic diversification" models, is being built in large 
part through the characterization  of antibodies elicited by simple haptens in 
mice.  The  response  to p-azophenylarsonate (Ars) 1 has  been  particularly  well 
studied and illustrates the general features of the consensus model. It also poses, 
and helps to illuminate, some of the outstanding issues of the diversity problem. 
When coupled to the protein keyhole limpet hemocyanin, Ars stimulates a 
vigorous antihapten response in all mouse strains. Monoclonal murine antibodies 
specific for Ars, isolated by the hybridoma technique (2, 3) may be classified into 
three  families  (4).  These  families,  designated  Ars-A,  Ars-B,  and  Ars-C,  are 
defined by the N-terminal amino acid sequences of their heavy chain variable 
regions (V, regions),  ~ which belong to different subgroups. The families deline- 
ated in this way are further distinguished both by serological characteristics and 
by the use of light chain variable regions (VL regions) of different subgroups. 
The  three families are  believed to  be  encoded by different sets  of germline 
genes, and the ability of a  mouse strain  to recruit a  particular family into its 
response to  Ars  is  an  inherited characteristic.  This  situation  exemplifies the 
frequently observed expression of multiple sets of germline genes in response to 
a single antigenic determinant. 
Inbred  strains  may vary genetically in  the spectrum of antibodies that are 
elicited by hapten. For example, A strain mice respond to Ars with antibodies of 
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"VM region" here refers to amino acid residues  1-121 of the heavy chain, which are encoded by 
three separate genes, VH, Dn, andJH. "VN segment", in contrast, is used to denote amino acid residues 
1-98 of the heavy chain, which are encoded by the Vn gene alone. Similarly, "VL region" refers  to 
amino acid residues 1-108 of the light chain, which are encoded by two separate genes, V, and  J, (or 
vx andJx).  "V, segment", in contrast, is used for amino acid residues 1-95, which are encoded by the 
V, gene alone. 
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which a major portion bears a cross-reactive idiotype (CRI) peculiar to that strain 
(5). The CRI is conventionally identified using a polyclonal rabbit antiserum that 
is raised against A/J mouse anti-Ars antibodies and rendered idiotypically specific 
by absorption on preimmune A/J immunoglobulin (5).  The CRI is measured in 
a radioimmunoassay that determines the degree of inhibition between the rabbit 
anti-CRI and radiolabeled A/J anti-Ars antibodies (5). Breeding studies between 
the  CRI-positive A/J  mouse strain  and  CRI-negative  strains  such  as  BALB/c 
show that expression of the CRI in the anti-Ars response is inherited as if it were 
determined by a  single autosomal dominant gene at a  locus linked to the Igh 
gene complex (6).  Linkage to Igh is a  feature common to many such idiotypic 
systems (7).  The expression  of one of the three  structurally  defined  anti-Ars 
families, Ars-A, shows the same strain distribution as the CRI, and so far all A/J 
antibodies bearing the CRI have been found to belong to this family (4).  Allelic 
diversity of this general kind is commonly observed in the expression of antibody 
families and of shared idiotypic specificities. 
The V, regions of the Ars-A family have been characterized in detail. Eight 
complete amino acid sequences are available (8-10),  seven from A/J and one a 
CRI-positive hybridoma product derived from the congenic strain C.AL 20, in 
which the heavy chain genes are  contributed by an  A  strain  genome and the 
light chain genes are from BALB/c. All the chains are closely similar in sequence 
and show <3 % overall variation. They all appear to be the products of a single 
A/J germline V~ gene or, in the case of C.AL 20, the BALB/c homolog of this 
gene. They probably also use a single germlineJ~ gene, identified as the homolog 
ofeitherJ~l orJ~2 in BALB/c (11, 12). Thus, the BALB/c genome can contribute 
V~ chains essentially identical to those of the A/J to make a CRI-positive antibody 
in response to Ars, provided that an appropriate V, chain is available from the 
A  strain  genome. A  light chain virtually identical to those of the Ars-A family 
has recently been reported (13) in an antibody elicited in BALB/c in response to 
the  hapten  2-phenyi  oxazolone.  A  similar  chain  has  also  been  found  in  a 
BALB/c  myeloma protein  (MOPC-173)  of unknown antigen  specificity  (14). 
Both proteins have heavy chains that differ from each other and both are unlike 
those of the Ars-A family. This is an example of the long-predicted production 
of novel antigen specificities by combinatorial association of VL and VH segment 
genes to form novel variable region pairs. 
Although members of the Ars-A antibody family are similar in many respects, 
several lines of evidence suggest that structural differences exist between them. 
First, they differ in the degree to which they display the CRI in the conventional 
radioimmunoassay  (15-17).  Some  are  strongly  CRI  positive,  some  are  only 
weakly positive, and some are CRI negative. Chain recombination experiments, 
using light and heavy chains from antibodies within the family that differ in their 
expression of the CRI, show that the heavy chain is largely responsible for the 
expression or nonexpression of the  CRI  and for  the degree of its expression 
(18).  Members  of  the  family  also  differ  in  their  expression  of  "private"  or 
"individual" idiotypes (16), in their affinity for Ars (19, 20), their fine specificity 
(19), and in the N-terminal  sequences of their heavy and light chains (15,  21, 
22). Variation in such properties within antibody families is a general phenome- 
non  and  is  sometimes very  extensive.  It  has  been  demonstrated  in  structural SLAUGHTER  AND  CAPRA  1617 
studies of antibodies against dextran (23), (4-hydroxy-3-nitrophenyl) acetyl (NP) 
(24), phosphoryl choline (PC) (25), oxazolone (13, 26), and the synthetic polymers 
GAT (copolymer of glutamic acid, alanine, and tyrosine) and GA (copolymer of 
glutamic acid and alanine) (27),  and has also been characterized in families of 
closely related myeloma proteins sharing specificity for antigen, including gal- 
actan-binding myeloma proteins (28) and inulin-binding myeloma proteins (29, 
30). 
The genetic basis for such variation is the subject of intense interest. As part 
of the analysis of the variation in the arsonate system, Southern filter hybridiza- 
tion studies have been carried out using V. segment DNA probes from Ars-A 
hybridomas to analyze the  germline DNA  of A/J  mice.  These  studies  have 
revealed several V. genes closely related to members of the Ars-A family (31, 
32).  However, use of a Js probe to detect the rearranged gene in hybridoma 
DNA has shown that productive rearrangements give rise to restriction fragments 
of the same size  in most hybridomas making Ars-A antibodies (33,  34).  This 
suggests that V. DNA from only one of the restriction fragments observed in 
digests of genomic DNA is  used  to  make antibodies of this  family and that 
somatic mutation plays a determining role in the diversification of the V. segment 
sequences. 
However, the extent of sequence diversity in the complete V. region, and the 
distribution of replacements between and within V., D., and JM segments have 
not  previously been  determined for  the  Ars-A  family.  These  issues  are  the 
subjects of the present report.  The amino acid sequences of five V. regions 
belonging to antibodies from the Ars-A family are described. The sequences of 
the corresponding V, regions have already been determined (8). The antibodies 
chosen for analysis were selected to represent the range of quantitative expression 
of the CRI seen among members of the family, extending from the most strongly 
CRI-positive HP 93G7 and HP R16.7, through the progressively more weakly 
CRI-positive HP 123E6 and HP 124E1, to the CRI-negative HP 91A3. These 
antibodies  also  differ  in  their  expression  of private  idiotypes  (16),  in  their 
reactivity with monoclonal antiidiotypic antibodies (35), and in their fine speci- 
ficity for antigen (19), but show similar affinities for the immunizing hapten Ars 
(19). The present study was thus designed to develop structural correlates of the 
CRI and to illuminate the genetic mechanisms that give rise to sequence varia- 
bility within the Ars-A family. The sequence of the prototype molecule for the 
series, HP 93G7,  has already been published (31),  and preliminary reports of 
the other sequences have also appeared (10,  36,  37).  The data in this paper 
supercede all previous listings for these sequences. 
The data  show that  the V. regions are closely related, but the differences 
between them are sufficiently numerous to permit discrimination among all of 
them. The structural variation in the heavy chains together with the variation in 
the corresponding light chains (8) provide a basis for interpreting the differences 
in the serological and other properties that the five antibodies display. 
Materials and Methods 
Preparation and Characterization of Hybridomas.  The five hybridomas secreting anti-Ars 
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limpet hemocyanin-Ars with the nonsecreting hybrid plasmacytoma cell line Sp2/0-Ag 14 
(38).  The  generation  of the  hybridomas,  which all  produce antibodies  that  are  IgG1, 
kappa,  has been  described  in  detail previously (15,  16).  HP 93G7  and  HP 91A3  were 
derived  in  one fusion,  but  since the  spleens  of two different  mice were  used,  it  is not 
known whether they arose from the same animal or different animals. HP 123E6 and HP 
124E1  arose  from a  second fusion,  and again,  the  spleens  of two different  mice were 
pooled.  HP  R16.7  was derived  in a  third  fusion and  was the  gift of Dr.  A.  Nisonoff, 
Brandeis University,  Waltham,  MA. The hybridomas were injected into CAF1 mice for 
the collection of ascites fluid containing large amounts of hybridoma antibody (2-5 rag/ 
ml).  In each case, the  hybridoma product was isolated from the ascites fluid by affinity 
chromatography on a column of Sepharose 4B conjugated with human gamma globulin 
that  had  been  derivatized  with  arsanilic  acid  (15).  Pertinent  data  on  the  serological 
characteristics of the five antibodies are summarized in Table I. 
Preparation and  Sequencing of Cyanogen Bromide (CNBr) Peptides.  Intact  hybridoma 
immunoglobulins  were cleaved with  CNBr  in  70%  formic acid (39).  The  heavy chain 
fragment that consisted of the disulfide-bonded pair of peptides extending from position 
21  to 81  and 82 to 142, respectively, was isolated by gel filtration on a Sephadex G100 
column equilibrated  with 5 M  guanidine-HCI. Incomplete cleavage at Met-20, however, 
produced a copurifying fragment in which the 21-81 peptide was lengthened to comprise 
the complete N-terminal  sequence  1-81.  After desalting on a  Sephadex G25M column 
equilibrated with 0.25 M ammonium hydroxide, and lyophilizing, the constituent peptides 
were  dissociated  by  complete  reduction  and  alkylation  (40)  and  were  desalted  and 
lyophilized as before. For HP 93G7, HP R16.7, and HP 124E1, the peptide 82-142 was 
separated from 21-81 and 1-81 by cation-exchange chromatography on a sulphopropyl- 
Sephadex column equilibrated  with  8  M  urea and 0.001  M  KCI at pH  3.4.  Elution was 
performed  with  a  gradient  of 0.001-0.2  M  KCI.  All peptides  were desalted  after  ion- 
exchange chromatography by dialysis against  0.02%  trifluoroacetic acid in water  using 
low molecular weight cut-off dialysis tubing, and were then lyophilized. The peptides 21- 
TABLE  I 
Inhibition of Binding in Various Assay Systems by Purified Hybridoma 
Products 
Unlabeled  inhibitor 
Nanograms required for 50% inhibition 
A.  B.  C. 
Rabbit anti-  Rabbit anti-  Rabbit anti- 
CRI/CRI*  Id 123E6/  Id 91A3/ 
93G7"  93G7" 
A/J anti-arsonate  15  200  25 
HP 93G7  12  32  12 
HP R16.7  9  Not done  10 
HP 123E6  50  87  86 
HP 124E1  2,900  48  16 
HP 91A3  >20,000  >20,000  25 
Arsonate  10 mM  2 mM  >100 mM 
Assay A. Canonical assay for CRI, showing diversity of degree of CRI 
expression  (15)  and  high  sensitivity  to  hapten  (17,  62).  Antibodies 
capable of inhibiting  by 50% (all except HP 91A3) are designated  CRI- 
positive. Assay B. Heterologous assay for idiotypic specificities shared by 
HP 93G7 and HP  123E6,  showing commonality among CRl-positive 
antibodies  and high sensitivity to hapten inhibition  (62). Assay C. Het- 
erologous assay for idiotypic specificities shared  by HP 93G7 and HP 
91A3, showing commonality among all Ars-A antibodies (4) and relative 
insensitivity to hapten inhibition  (E. Milner, personal communication). 
Radiolabeled.  Assays used 10 ng ~25I-labeled tracer antibody and slightly 
less than an equivalent amount of antiidiotype. SLAUGHTER  AND  CAPRA  1619 
81 and 1-81 were subsequently separated by gel filtration on a Sephadex G75 SF column 
equilibrated with 0.25 M ammonium hydroxide. In the case of HP  123E6,  the peptide 
82-142  could be  only partially separated  from  1-81  and  21-81  by cation-exchange 
chromatography, and required further fragmentation to produce homogeneous peptides 
for sequencing (see below).  HP 91A3 had a Met at position 105 that was not present in 
the other antibodies. During CNBr cleavage, the 82-142 peptide was therefore split into 
two fragments. The 82-105  fragment remained disulphide bonded to the peptides 21- 
81  and  1-81  and after reduction and alkylation was successfully  purified by the same 
procedure as was used for HP 93G7, HP R16.7, and HP 124E1. The 106-142 fragment, 
however, was recovered separately during the initial G100  gel filtration step and was 
subsequently isolated from co-chromatographing heavy chain constant region peptides by 
reverse-phase,  high  performance liquid  chromatography (HPLC)  (for conditions, see 
below). 
Peptides extending from position 82 were sequenced to position 121, the end of the 
VH region, except for the peptide 82-105 from HP 91A3, which was sequenced to its C- 
terminus. Peptides extending from position 21  could usually be sequenced only as far as 
position 70. Residues between positions 70 and 81 were identified after tryptic digestion 
(see below). Residues at positions 1-40 were identified by sequence analysis of intact heavy 
chains isolated by gel filtration on a G100 column equilibrated with 5 M guanidine-HC1 
after complete reduction and alkylation of the parent immunoglobulin. 
Preparation and Sequencing of Tryptic Peptides.  CNBr peptides  21-81  or  1-81  were 
digested with TPCK-Trypsin (Worthington Biochemical Corp., Freehold, N  J). Fragments 
were isolated by gel filtration on a Sephadex G50 SF column equilibrated with 0.25 M 
ammonium hydroxide, and by reverse-phase HPLC using an RP300 column (Brownlee 
Labs Inc., Santa Clara,  CA).  For the  HPLC separation, initial conditions included an 
aqueous solution of 0.02% trifluoroacetic acid in water and elution was performed with a 
gradient of 0-40% of a mixture containing 70% acetonitrile and 30% isopropanol acidified 
with 0.02% trifluoroacetic acid. 
The mixture ofCNBr peptides 21-81 and 82-142 from HP 123E6, which was obtained 
during cation-exchange chromatography, was further processed to produce pure peptides 
for  sequencing by citraconylating the  mixture  (40)  and  digesting with trypsin.  This 
procedure fragmented the peptide 82-142 by cleavage at arginines in positions 84, 98, 
and 101, but left the peptide 21-81  intact. Separation of the various components of the 
resulting  mixture  was  effected by  gel  filtration on  a  column  of Sephadex  G50  SF 
equilibrated  with  0.25  M  ammonium  hydroxide.  It  was  possible  to  obtain  complete 
sequences  of all  tryptic peptides  encompassing regions of the  molecules not already 
sequenced using unfragmented CNBr peptides. 
Sequencing  Methodology.  Automated amino acid sequence analysis was performed using 
Beckman 890C or 890D amino acid sequencers (Beckman Instruments, Inc., Palo Alto, 
CA). 0.25 M or 0.1  M Quadrol programs were used in conjunction with the nonprotein 
carrier Polybrene (41). The phenylthiohydantoin amino acid derivatives were identified 
by HPLC using both a Waters RCM C18 and RCM CN column (Waters Associates Inc., 
Milford, MA) for each determination, and by amino acid analysis after back-hydrolysis in 
selected cases. Quantities of peptides sequenced in individual runs varied from 200 pmol 
to 10 nmol and repetitive yields measured 92-95%. 
Results and Discussion 
The  V.  region amino acid sequences of five A/J anti-Ars antibodies of the 
Ars-A family, which differ in  the degree  to  which they express  the  CRI,  are 
shown  in  Fig.  1.  The  sequences  are  complete  except  in  two  respects.  First, 
uncertainties remain between positions 55 and 63 in HP 123E6.  All analyses in 
this paper exclude from consideration this region of HP  123E6.  Second, it has 
proved  impossible to identify the residue at position  55  in  HP  93G7  and  HP 
124E1  using conventional techniques (see Materials and Methods). In both cases, 1620 
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FIGURE  l.  Antiarsonate hybridoma heavy chains differing with respect to their expression 
of the CRI. Comparison of amino acid sequences of heavy chain V regions with that of HP 
93G7 (81). (  ) identical residues; (a) gap introduced to maximize  homology; parentheses 
indicate region in which no assignments  are availab]e. The heavy chains are given in order of 
their capacity to inhibit the reaction between A/J serum andarsonate and its rabbit anti- 
idiotype (see Table I). Numbering is sequential. Complementarity-determining  regions are 
outlined. A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys;  L, Leu; M, 
Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; Y, Tyr; X, modified 
residue (see text). 
automated amino acid sequencing yielded no compound giving a consistent signal 
in the chromatographic systems used for identification, and there was a  sharp 
fall  in  repetitive  yield  upon  sequencing  through  this  position.  However,  the 
amino acid sequence of the tryptic peptide of HP 124E1 extending from position 
39 to 65 has also been analyzed in a procedure which uses a dipeptidyl peptidase 
for fragmentation of the peptide followed by gas chromatography-mass spectrom- 
etry for identification of the dipeptides (42, 43). This analysis yielded an identi- 
fication of Asn at position 55 in this molecule (H. Krutzsch, personal communi- 
cation).  In addition,  nucleotide sequence analysis of a  V,  region cDNA clone 
made  from  the  93G7  cell  line  (31)  showed  that  in  HP  93G7,  position  55  is 
encoded by an Asn codon. In both molecules, therefore, it appears that Ash is 
present at position 55 but is modified in a  way that precludes identification by 
conventional procedures.  In HP R 16.7, however, Asn was identified at position 
55 by normal means.  In HP 91A3,  Lys was found to be substituted for Asn at 
this position. 
ars-A  V. Regions are Closely Related Members of a Single Subgroup  (VnV) but Are 
Homologous to  Chains  of the  VjI Subgroup.  Fig.  1 presents  the  five V.  region 
sequences in comparison with the sequence of the strongly CRI-positive molecule 
HP  93G7.  All  the  chains fall within  the  VHV  subgroup  (44)  and constitute a 
closely related set in which none of the sequences differs from the prototype at 
more than 12 positions. The V. region amino acid sequence of the CRI-positive 
A/J antiarsonate antibody HP  36-65,  which  has been  deduced from a  DNA 
sequence (32), also belongs to this family. 
The  V.  segments of these antibodies share residues  that differentiate them 
from  all  other  known  antibody  families.  They,  therefore,  are  believed  to  be 
encoded by a  separate germline gene or set of germline genes. However, they 
are closely homologous to V. segments of the VHII subgroup (44), including the SLAUGHTER  AND  CAPRA  1621 
antidextran (anti-Dex) antibody family in BALB/c bearing the Dex CRI (23) and 
the  anti-NP  antibody  family  in  C57BL/6  that  bears  the  NP  b idiotype (24). 
Representative comparisons are  shown in  Fig.  2.  HP  93G7  differs from the 
prototype Dex-positive myeloma protein, MOPC-104E, by 21 residues of the 98 
in the V. segment, and differs from the prototype Npb-positive antibody, B1-8, 
by 22 residues. The single most closely related chain that has been completely 
sequenced is  that  of the  BALB/c  myeloma protein  MPC  11  (45).  This also 
belongs to the VaII subgroup and its V. segment bears 20 differences from HP 
93G7. The heavy chain N-terminal amino acid sequences of antibodies belonging 
to the Ars-B family also belong to the VaII subgroup (4, 44) and they exhibit a 
level of homology to antibodies of the Ars-A family comparable to other VHII 
sequences. 
The 93G7  V. segment is also related to,  but distinctly different from, the 
sequence of a pool of antiarsonate antibodies derived from the serum of hyper- 
immune A/J mice after enrichment of the CRI-positive component by isoelectric 
focusing (46). The incidence of differences, which number 30 in the VH segment 
(Fig. 2), is anomalously large when compared with the close relationship among 
monoclonal members of the Ars-A family. This parallels the situation in the light 
chains, where it was also found that the hybridoma products were more closely 
related to each other than they were to the serum sequence (8). This suggests 
that either a different set of germline genes encodes the CRI-positive antibodies 
expressed  in  A/J  hyperimmune serum or  that  the serum antibody structure 
represents a consensus sequence for an inhomogeneous pool that contains CRI- 
negative antibodies of the Ars-B family as well as the CRI-positive antibodies of 
the Ars-A family. 
The Different  V,~ Segments Probably Arise from a Single Germline VH Gene by Somatic 
Mutation.  In antibodies of the Ars-A family, the segment encoded by the VM 
gene extends from position 1 to 98 of the mature heavy chain (34).  Siekevitz et 
al.  (34) have cloned Eco R1  restriction fragments of embryonic A/J DNA and, 
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Relationship of heavy chains of Vail subgroup and of A/J serum antiarsonate 
with an antiarsonate hybridoma heavy chain. Comparison of amino acid sequences of heavy 
chain V  regions of MPC  11  (45),  MOPC-104E (61),  and HP BI-8 (24),  and of A/J serum 
antiarsonate (46) with that of HP 93G7 (31).  (  ) identical residues; (a) gap introduced to 
maximize homology.  Numbering is  sequential.  Complementarity-determining regions are 
outlined. For single letter code for amino acid residues, see legend to Fig. 1. 1622  SEQUENCE DIVERSITY OF  ANTIARSONATE ANTIBODIES 
among inserts which  hybridized strongly to a  VH  segment DNA  probe  made 
from the CRI-positive cell line 36-65,  they distinguished three different genes 
by restriction mapping and DNA sequencing. One had a  sequence identical to 
the V.  segment expressed  by the  36-65  cell  line.  The amino acid sequences 
described in the present paper are best interpreted as having been derived from 
this germline gene. The other two genes, although extremely similar to the first, 
encode at least eight amino acids that are different from it. Only one of these 
amino acids has been found in any sequences of members of the Ars-A family. 
This result represents  the strongest evidence currently available that a  single 
germline 11, gene is used by members of the Ars-A family, and that differences 
in  their  VH  segment  sequences  must  be  ascribed  predominantly to  somatic 
mutation. However, it does not exclude the possibility that sequence information 
from portions of more remotely related genes is occasionally used by the Ars-A 
family after  unequal  crossing  over  or  gene  conversion  events.  A  thorough 
investigation of the  possibility that  multiple germline V,  segment genes  may 
contribute to intrafamily variation has also been conducted for BALB/c anti-PC 
antibodies of the T15  family (47)  and for C57BL/6 anti-NP antibodies of the 
NP  b family (24).  In these cases,  too, the amino acid or DNA sequences of the 
family of expressed V. segments were compared with the nucleotide sequences 
of the set of germline V,, genes most closely related to them. Although several 
closely similar V, genes were identified and sequenced in each  family, it was 
apparent in both cases that the expressed proteins nearly always derived from 
only one  germline gene  of the  set.  These  observations  form the  basis  of an 
emerging consensus of opinion that somatic mutation plays a  dominant role in 
diversification of the V segment sequences within all such antibody families. 
Loss of CRI Is Due to Mutational Divergence from  the Germline Sequence.  Fig.  3 
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Relationship of antiarsonate hybridoma VM segments to a germline V. segment 
gene. Comparison  of amino acid sequences  of V. segments  with the sequence encoded  by the 
genomic clone MdCR11 (34). (  ) identical  residues. Numbering is sequential. Complemen- 
tarity-determining  regions are outlined. For single letter code for amino acid residues, see 
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shows the VH  segment amino acid sequences of the five antibodies compared 
with the sequence encoded by the genomic clone XIdCR11, a representative clone 
bearing the V, gene used by members of the Ars-A family (34).  The series of 
five expressed antibodies shows differences from the germline sequence at a total 
of 13 positions of the 98 in the VH segment (13%). All of the replacements can 
be accounted for by single nucleotide substitutions. The number of differences 
shown by each antibody (excluding secondary modifications of Asn-55) ranges 
from two for HP R 16.7 to seven for HP 91A3. It is noteworthy that the antibodies 
that are most strongly CRI-positive show fewer differences from the germline 
sequence than  antibodies  that  are weakly CRI-positive  or CRI-negative.  This 
observation is consistent with the hypothesis that the germline encodes the amino 
acid sequence of a strongly CRI-positive antibody, and that reduction in the level 
of CRI expression in  members of the Ars-A family is due to divergence from 
this sequence by somatic mutation. 
This result has a  parallel among the corresponding VL segments (8).  Direct 
information about DNA sequences of VL genes used by members of the Ars-A 
family is not yet available. However, if it is assumed that a single germline gene 
encodes all known VL segments in this family, and if it is further assumed that 
the most common amino acid at each position is encoded by this germline gene, 
then the most strongly CRI-positive antibodies are again found to have the fewest 
differences from the putative germline sequence (8, 9, 37). 
There Is Clustering of  Positions Bearing Substitutions in the V, Segments.  The linear 
distribution  of VH  segment positions  bearing substitutions  from the germline 
sequence  is  clearly  different from  that  expected  on  the  basis  of a  random 
distribution of mutations. The incidence of amino acid replacements within the 
first and second complementarity-determining  regions (CDR) (14.9%), calculated 
as the total number of residues different from the germline sequence in these 
regions divided by the total number of residues sampled, is 8.3 times higher than 
the corresponding incidence in the framework regions (1.8%), not counting the 
posttranslational modifications at position 55. CDR2 provides a special focus of 
variability, with an incidence of replacements (19.7%)  that is 9.0  times higher 
than the incidence in the remainder of the V. segment (2.2%). Historically, the 
hypervariable regions in the V. and VL chains were delineated by comparison of 
chains that belonged to the same variable region subgroup but which had been 
selected without regard to the antigen specificity of the parent myeloma proteins 
(48-50). The localization of differences could thus be interpreted as due, at least 
in  part,  to  differences in  antigen  specificity, since most  of the hypervariable 
regions were subsequently shown to contain complementarity-determining  amino 
acids.  More  recent comparisons,  such  as  the present  study,  have  focused on 
antibodies that belong to the same family. These antibodies share not only VH 
and VL subgroups in common, but also specificity for the same antigen. In some 
of these studies, hypervariability in CDR3 of the heavy chain has been observed 
(23,  25),  but  variability in  CDR1  and  CDR2  has in  no case been prominent. 
There is thus a general trend towards diminution of hypervariability in the CDRs 
and this has usually been attributed to selection against mutations in these regions 
based on the requirement for binding to the same antigen (51). The present set 
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CDR2 (as well as CDR3; see below) provides a conspicuous focus for variability. 
It may be important that these chains, unlike the ones sequenced in other studies, 
have  been  drawn  from  antibodies  showing  a  very broad  range  of idiotypic 
expression. This  unusual result  may thus be associated with variation in  CRI 
expression. Such an interpretation receives support from the observation that 
the binding  of CRI  and anti-CRI  antibodies  is  largely inhibitable  by hapten, 
suggesting that residues in the CDR play a role in expression of the CRI (17). 
Several  VH Positions that Bear Substitutions  are "Hot Spots" of Variation.  The 22 
amino acid residues that differ from the germline V. sequence are located at 
just 13 positions. Seven of these positions bear replacements in one V. segment 
only, but three bear replacements in two V. segments and three bear replace- 
ments in three V. segments. There is thus a clustering of replacements in "hot 
spots" of variation. Examples of these hot spots are to be found in both framework 
and hypervariable regions. Once again, since this set of antibodies was selected 
to maximize variation in the degree of expression of the CRI,  some positions 
may owe their high incidence of replacements directly or indirectly to selection 
for loss of the CRI. 
At least two of the multiply substituted positions,  14 and 58, show identical 
repeated  replacements.  At  position  14,  three  V.  segments  (HP  123E6,  HP 
124E1, and HP 91A3) have a variant Thr in place of the germline-encoded Ala, 
and at position  58,  three V. segments (HP 93G7,  HP  124E1,  and HP  91A3) 
have a  variant  Ile  in  place  of the  germline-encoded Thr.  In  both  cases,  the 
substitutions are found in V. segments drawn from at least two different animals 
in independent fusion experiments. Such repeated substitutions are likely to be 
a  common feature of antibodies belonging to  the Ars-A  family since further 
substitutions identical to ones reported here have been discovered at five posi- 
tions in chains sequenced independently by Margolies et al. (21, 34, and unpub- 
lished observations). They include the replacement of the germline Ala by Thr 
at position 9  in two further proteins, HP 45-223  and HP 3D10, and a further 
example of the replacement of the germline Ala by Thr at position  14  in the 
protein  HP  45-223  (21,  and  unpublished observations summarized in  34).  A 
repeat of the replacement of the germline Gly by Val at position 56, of germline 
Lys by Asn at position 63,  and of germline Ser by Gly at position 85  have all 
been identified in another antibody, HP  1  F6 (Margolies, personal communica- 
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FIGURE 4.  Relationship  of antiarsonate hybridoma  D. segments  to a germline D. segment 
gene. Comparison  of amino acid sequences  of D. segments  with the sequence  encoded  by the 
DrL~6., gene of BALB/c (52). (  ) identical residues. For single letter code for amino acid 
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tion). Even in this wider series of repeated substitutions, however, no correlation 
between substitutions at different positions is yet discernible. Repeated substitu- 
tions of this kind have also been observed among the VL segments of the Ars-A 
family (8,  37) and  among  chains  from  other  systems such as the  VL segments 
from inulin-binding  myeloma proteins (30). The V, segments from antiarsonate 
antibodies of the Ars-A family, however, provide the best evidence so far that 
the  phenomenon  may arise  from  repeated  yet independent  somatic  mutation 
events. 
Dn Segment Diversity Adds Greatly to Structural Variability within  the Ars-A Family 
and Is Probably  Generated  Somatically.  The  D.  segment,  which  encompasses a 
portion  of CDR3,  provides a  second  major  focus for differences between the 
members of the Ars-A family. Its N-terminal boundary lies between positions 98 
and 99, such that the codon for position 98 is supplied by the VH gene and the 
codon for position 99  is supplied by the D~ gene (34).  There  is no junctional 
diversity at the  V.-D, boundary since all  five DH segments have the same first 
amino acid,  Set.  The C-terminus  of the D. segment is located at position  107, 
which marks  the site of joining between the Dn and Jn genes.  At this position, 
there are three different residues in the five molecules, an example of  junctional 
diversity that will be discussed in the next section. 
Between  the  boundaries  of the  D.  segment,  the  five chains  differ  in  both 
sequence and length.  After the introduction of gaps in the shorter sequences to 
maximize  homology (Fig.  1),  it  is  found  that  all  of the  variation  in  length  is 
confined to the second and third  DH segment positions (positions  100 and  100a 
in the heavy chain).  Also located at these two positions are five of the nine DH 
segment residues that differ from the HP 93G7 prototype. The remaining four 
differences are scattered over four positions in a  less variable region or "core" 
segment of D. extending  from position  101  to  106.  Two of these differences 
occur in  HP  123E6 and  HP  124E1,  respectively, and  two occur in  HP 91A3. 
One of the two differences in HP 91A3, the substitution of a  Met for a  Ser at 
position 105, would require a double-base change. 
Although there exists no direct information  on germline DH genes in the A/J 
mouse, nucleotide sequences for 10 different D~ genes have so far been described 
in  the  BALB/c (52).  These  fall  into  three  families, DFL16  , Osp2, and  Ds~. The 
prototype gene for the DrLle family, Dr/~16.t, is the most closely homologous to 
the D. segment core of the Ars-A antibodies. A  comparison is shown in Fig. 4. 
All of the chains share a  common difference from DFL16.1, the substitution of a 
Gly for a Ser at position  104. Since this Gly is present in all the antibodies, it is 
most likely to be encoded in  the germline  gene or genes that  give rise to this 
family  of  D.  segments.  This  suggests  that  a  hitherto  undescribed  germline 
member of the DFL16 gene family is recruited  in these antibodies.  The number 
of germline Drrm genes encoding the different D. segments in the Ars-A family 
is unknown, but an attractive possibility is that a single gene, which encodes the 
prototype core sequence found in  HP 93G7 and  HP R16.7,  is used by all the 
molecules. Under this hypothesis, the amino acid differences seen in HP 123E6, 
HP 124E 1, and HP 91 A3 result from somatic mutation, and the smallest numbers 
of mutations are once again found in the most strongly CRI-positive antibodies, 
as was the case in the VH segments. The relationship of this hypothetical single 1626  SEQUENCE DIVERSITY OF  ANTIARSONATE ANTIBODIES 
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FIGURE 5.  Relationship of antiarsonate hybridoma J. segments to a germline J. segment 
gene. Comparison of amino acid sequences of  J. segment with the sequence encoded by the 
Jn2 gene of BALB/c (57, 58). (  ) identical residues. For single letter code for amino acid 
residues, see legend to Fig. 1. 
gene to DFLI6.1  is, of course, unknown. It may represent the A/J allelic counterpart 
to the BALB/c DFL16.1 gene or it may define a new locus within the DFL16  complex. 
In the comparison of the Ars-A  D. segments with the sequence encoded by 
DFL16.1 (Fig. 4), amino acids at positions 99, 100, and 100a appear as hypervariable 
N-terminal  extensions  to  the  core  sequence.  Although DFLt6.1 encodes  a  Tyr 
immediately preceding the core sequence,  this particular residue has not been 
identified in any of the antibodies at position  100a but is always replaced by a 
different amino  acid.  It  is  not  known  to  what  extent  nucleotides  from  the 
germline codon at this position are used to create this diversity, but it is interesting 
to note that while the second and third nucleotides of a hypothetical Tyr codon 
are appropriate  for creating a  codon  for the  His in  HP 93G7,  the Asn in HP 
R16.7,  and the Asp in  HP  124E1,  they are  inappropriate  for creating codons 
for the Arg in  HP  123E6  and the Ser  in  HP 91A3.  Extensions similar to the 
ones described  here  have been  noted to occur in  D.  segments in a  variety of 
systems (52, 53). They are characterized by the presence of amino acids at either 
the  N-  or  C-terminus  of a  Dn  core  sequence  that  are  determined  by  codons 
unknown as parts of any germline D, gene related to the one encoding the core. 
The  genetic  origin  of amino acids in  extensions of this  kind is  unknown, but 
some radical explanations are  current.  One possibility is the  involvement of a 
second D, gene that becomes attached to the core gene in a Du-D,,joining process 
(52).  However, this explanation is currently considered less attractive (54) than 
the  alternative  possibility  that  the  amino  acids  result  from  the  addition  of 
nucleotides at the DNA level during V,-D, joining by the template-independent 
action of a  terminal deoxynucleotidyl transferase, thus creating a  so-called  "N 
segment" (53).  A  possible objection to the latter mechanism in the present case 
is that it lacks the specificity required to place the same amino acid, Ser, at the 
N-terminus of the extension in every molecule. However, this objection may be 
circumvented by asserting that the Ser is essential in some way for the integrity 
of the antibody molecule or for its ability to combine with antigen. The most 
common length for the extension piece in  the present set of antibodies is two 
residues, but HP 123E6 and HP 91A3 have extensions with the atypical lengths 
of three and one residue, respectively. It is not yet known whether any signifi- 
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expression of the CRI. Variation in the number of residues present within CDR3 
has been recognized for a  long time and it is now known that variation in the 
lengths of D. segment extension pieces contributes to this. However, there is a 
strong tendency toward conservation of the number of residues in CDR3 among 
antibodies of a family binding the same antigen (see, for example, 39, 56). The 
variation in length observed in the Ars-A family provides an interesting departure 
from this trend, the stereochemical implications of which remain to be deter- 
mined. 
Modest J, Segment Diversity Is Somatic in Origin.  The JH segment extends from 
the site of D.-J. joining at position  107  to the C-terminus of the VH region at 
position 121. All fiveJ, segments are different. However, they all have sequences 
that  bear  closest  homology  to  the  germline Jn2  gene  of BALB/c  (57,  58). 
Although data about germline Jn genes in the A/J mouse are incomplete at the 
DNA level, this result suggests that all five J. segments are the products of a 
single germline gene representing the A/J homolog ofJH2. A comparison of the 
five Ars-A J. segments with the sequence encoded byJ,2 is shown in Fig. 5. The 
chains differ from the germline sequence at one or two positions each. The total 
of eight amino acid differences are distributed over six positions and the only 
one of these positions that shows more than one replacement is the junctional 
position,  107. This distribution of substitutions is consistent with the hypothesis 
that the germlineJ. gene used by these antibodies encodes the same amino acid 
sequence as BALB/cJH2 and that all differences from this sequence are generated 
somatically. In the J. segment, there is no correlation between the numbers of 
differences from germline and the degree of expression of the CRI in the parent 
antibody. 
The junctional diversity at  position  107  cannot be accounted for solely by 
variation in the position of D.-JHjoining (for a general discussion of gene segment 
joining, see 59). TheJ,2 gene has a Tyr codon, TAC, at the first position (57, 
58) and Tyr is present in two of the five antibodies, HP  123E6 and HP  124E1. 
HP 93G7 has an Asp at this position, encoded by a GAC codon (31). This could 
have been generated by a joining event that brought a hypothetical G from the 
3' end of the D,, gene into apposition with AC from the Tyr codon at the 5' end 
of the J,, gene, thus creating a hybrid codon for Asp. Alternatively, it could have 
been generated from the J, Tyr codon by a mutational change of the first base 
from T  to  G.  Both  HP  R16.7  and HP  91A3  have a  Ser at position  107,  the 
former encoded by a  TCC codon (A.  Maxam, personal communication). This 
codon could have been generated twice by two independent mutations of the 
second base  in  the Tyr codon from A  to  C.  It could also have arisen by the 
formation of a hybrid codon between a DH gene and a J, gene. However, there 
is no way both the Asp codon in HP 93G7 and the Ser codons in HP R16.7 and 
HP  91A3  could  arise  by  this  mechanism if the  same D,  and JH  genes  were 
involved,  whatever the position  of joining  might  have  been.  The  only  valid 
alternatives to the mutational explanation would, therefore, be ones that relied 
on the existence of two D, genes with different nucleotide sequences at their 3' 
ends or twoJ, genes with different nucleotide sequences at their 5' ends. 
Structural Basis of the CRL  The present study represents a  sampling of V. 
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Some of the positions at which these substitutions occur, but almost certainly not 
all, form parts of the determinants comprising the CRI. Since the study excludes 
substitutions that compromise antigen binding, the observed variants may rep- 
resent  only  a  subset  of residues  that  provide  attachment  sites  for  anti-CRI 
antibodies.  However,  it  is  this  subset  which  is  permitted  to  vary  during  an 
antigen-driven immune response and which therefore has potential physiological 
significance as  the  basis  for  selection  between  idiotypically distinct  antibody 
forms. 
In the three antibodies showing diminished expression of the CRI, there are, 
in total, 20 positions in the heavy chains and 7 positions in the light chains that 
bear residues not present in one or other of the strongly CRI-positive antibodies. 
These residues signal positions with potential involvement in the determinants 
comprising the CRI.  Since the CRI itself is defined by a rabbit anti-CRI serum 
that is polyclonal, and the anti-CRI is conventionally prepared against A/J anti- 
Ars serum antibodies that are also polyclonal (5), it is impossible on the basis of 
serology alone to eliminate any of these positions as possible sites for attachment 
of anti-CRI  antibodies.  Some of the  difficulties inherent in  the conventional 
definition of the CRI  can be avoided if idiotypic specificities defined only in 
terms  of  monoclonal  antiidiotypic  antibodies  are  considered.  However,  the 
problem  is then  merely transformed into  one of identifying the antigenically 
dominant determinants comprising the  CR!  among the various  determinants 
recognized by the monoclonal reagents, since any one of these determinants may 
contribute only a small part to the total antigenicity of the V regions. 
Despite these difficulties there are indications of the way residues comprising 
the CRI are localized. For example, the ability of hapten largely to inhibit the 
interaction of CRI and anti-CRI suggests that residues in the CDR are important 
constituents of determinants comprising the CRI (17). Also, antibodies belonging 
to the Ars-A family but differing with respect to  their expression of the CRI 
show, in chain recombination experiments, that substitutions in the heavy chains 
are  predominantly  responsible  for  variation  in  idiotypic  expression  (18).  If 
attention is accordingly restricted to the CDR in the heavy chain, the number of 
positions which have potential roles as constituents of the CRI can be narrowed 
to  14.  One of these positions is in  CDR1,  four are in  CDR2,  and nine are in 
CDR3. Some of these positions may eventually be eliminated from consideration 
if they are found to bear identical substitutions in further strongly CRI-positive 
antibodies.  The  role  of others  may be  defined in  the  course of site-specific 
mutagenesis experiments. On the other hand, structural analysis of additional 
CRI-negative antibodies of the Ars-A family may result in the identification of 
further positions at which substitutions are able to modify CRI expression. 
Factors Underlying the Pattern of Variation.  Various aspects of the distribution 
of substitutions are associated with the loss of CRI in this set of molecules. These 
include the greater incidence of replacements in antibodies showing diminished 
expression of the CRI, the unusual degree of clustering of replacements in the 
CDR, and the localization of much of the variation in hot spots at which antibodies 
with weakened CRI expression can be distinguished from strongly CRI-positive 
antibodies. However, since the proportion of variants that have a  direct effect 
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be determined by factors only indirectly related to variation in the degree of 
expression of the CRI. 
The first of these factors is mutation rate. In the absence of selection, mutations 
in the V regions accumulate through time to an extent that is believed to depend 
on the duration of developmental time in which the expressed variable region 
genes are subject to a high rate of somatic mutation (13, 25). The distribution 
of substitutions is controlled to an unknown extent by differences in the rates at 
which mutational changes and other somatic alterations arise at different sites. 
It is possible that mutations at positions affecting expression of the CRI occur 
only rarely relative to mutations at other positions and therefore arise predomi- 
nantly in molecules sharing a  high probability of bearing replacements at sites 
irrelevant to expression of the CRI.  Selection for reduction in CRI expression 
will then give rise to molecules that bear replacements at several positions which 
share only a relatively high mutation rate in common. This may account for the 
otherwise anomalous  observation  of concordant variation  in  the  numbers of 
substitutions in  both  the V. and VL chains, despite the lack of any detectable 
dependency of CRI expression on variation in light chain structure (18). It may 
also account for the existence of hypervariable positions at which the replace- 
ments do not appear precisely in accord with the level of CRI expression, such 
as positions 58 and 100 in the heavy chain. Hypervariability at positions that are 
believed to be unimportant for expression of the CRI may also be accounted for 
in this way. For example, position  14 in the heavy chain bears a substitution in 
all  three molecules showing reduced or absent  expression of the CRI,  but  is 
located in a framework region where it may be remote from the site of interaction 
with antiidiotypic antibodies. 
The second factor that modulates the distribution of mutations is the stabilizing 
selection which suppresses amino acid substitutions at functionally crucial sites 
and permits only "conservative" changes (substitution of acidic residues by acidic, 
basic by basic, hydrophobic by hydrophobic, etc.) at other locations. The require- 
ment for antigen binding is able to mediate such selection. The replacements 
that are found in  the face of such stabilizing  selection are ones which do not 
compromise the general integrity of the three-dimensional structure and cause 
no  significant  alterations  in  the  specific  sites  that  interact  with  antigen.  An 
indication of the action of this and other kinds of selection may be obtained 
during sequencing studies at the nucleic acid level, where it will be possible to 
measure ratios  of the  incidence of silent  and  nonsilent base  changes and  to 
compare them to  the ratios  expected on  the basis of unselected mutation.  A 
significant elevation of base changes that give rise to amino acid substitutions 
can be taken as an indication of differential selection (60). 
The  third  factor  controlling  the  distribution  of variation  is  selection  for 
divergence of amino acid sequences. Although overt selection for loss  of CRI 
expression has been imposed here during the choice of antibodies for sequence 
analysis, the patterns of variation that result from this selection may reflect not 
only the distribution of mutations affecting the CRI itself but also the incidence 
of mutations affecting other,  as yet unidentified properties  which are closely 
correlated with expression of the CRI in vivo. Possible examples of such prop- 
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of distinct idiotypic specificities. 
These  various factors are  able to interact  in a  complex way to produce  the 
patterns  of variation  seen  in  the  Ars-A  family.  They  are  presumably  no  less 
actively at work in other systems of expressed antibodies,  and it is perhaps the 
complexity of their interaction, more than any other component of the antibody 
diversity problem, which remains for the future to elucidate. 
Summary 
VH region amino acid sequences are described for five A/J anti-p-azophenylar- 
sonate (anti-Ars) hybridoma antibodies for which the VL region sequences have 
previously been determined,  thus completing the V domain sequences of these 
molecules.  These  antibodies  all  belong  to  the  family designated  Ars-A  which 
bears the major anti-arsonate cross-reactive idiotype (CRI) of the A strain mouse. 
However, they differ in  the degree to which they express the CRI in standard 
competition radioimmunoassays. Although the sequences are closely related, all 
are different from each other.  Replacements are distributed throughout the VH 
region and occur in positions of the chain encoded by all three gene segments, 
Vm D,, andJ,.  It is likely that somatic diversification processes play a dominant 
role in producing the sequence variability in each of these segments. The number 
of  differences  from  the  sequence  encoded  by  the  germline  is  smallest  for 
antibodies that express the CRI most strongly, suggesting that somatic diversifi- 
cation is responsible for loss of the CRI in members of the Ars-A antibody family. 
There is an unusual degree of clustering of differences in both CDR2 and CDR3 
and many of the substitutions are located in "hot spots" of variation.  The large 
number  of differences between the chains  prohibits  the  unambiguous  identifi- 
cation  of  positions  at  which  alterations  play  a  major  role  in  reducing  the 
expression  of the  CRI.  However, the  data  suggest that  the  loss of the  CRI is 
associated with a definable repertoire of somatic changes at a restricted number 
of highly variable sites. 
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